Needham maintains Astrana Health at Buy, raises price target to $45 from $41

Needham reaffirmed its Buy rating for Astrana Health and increased its price target to $45 from $41, suggesting a 15.4% upside from the Nov 5 close of $39.01, according to the firm.

Original reporting
Published Nov 6, 2026, 11:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 11:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Needham maintains Astrana Health at Buy, raises price target to $45 from $41 — source image
Decision brief

The 30-second read

$ASTHBullishMed
01

Why it matters

The target increase reflects improved expectations but lacks accompanying operational updates.

02

Market read

A modest analyst upgrade that may generate short‑term buying pressure.

03

What to watch

No new earnings or product news; price may remain range‑bound despite higher target.

Relevance 5/10Novelty 6/10Timing: today

Background

Astrana Health is a micro‑cap biotech listed on Nasdaq; analyst coverage is sparse.

Company-level read

Ticker impact

$ASTHBullishMedium confidence
Context

Needham raised Astrana Health's price target to $45 from $41, indicating a fresh bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Target raise is a new catalyst; no other material news, so impact is modest.

Market effects

Positive signal for the healthcare sector may lift peer sentiment.

Limited to U.S. small‑cap healthcare stocks.

Low

Counterpoint

Target raises can be premature if underlying fundamentals remain unchanged.

Key entities

  • Needham & Company

    Equity research firm that issued the rating upgrade.

  • Astrana Health

    Biopharmaceutical company focused on rare diseases.

Related articles

$ASTHHighAI 8/10

Astrana Health Earnings Call Highlights Growth and Deleveraging

Astrana Health (ASTH) reported Q3 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). The company highlighted organic growth, debt reduction, and favorable Medicare trends. Management maintained full-year guidance, expecting revenue of $3.9B-$4B and adjusted EBITDA of $261M-$274M. Challenges include Medicaid pressure and seasonality.

$ASTHMed

Astrana Health 3Q 2026: Revenue $1.02B, EPS $0.26 — 10-Q Summary

Astrana Health reported 3Q 2026 revenue of $1.02B, up 7% YoY, and net income of $13.0M, compared to $373K last year. Growth was driven by 9% increase in capitation revenue. Care Partners saw 8% revenue growth and 94% operating income rise, while Care Delivery revenue increased 5% but operating loss widened. Care Enablement revenue rose 5% with 4% higher operating income. Astrana managed 29 IPAs and 1.5M patients as of September 30, 2026.

$ASTHMed

Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA

Astrana Health Inc (ASTH) reported Q3 2026 earnings, highlighting record revenue and EBITDA growth. CEO Brandon Sim discussed Medicaid membership attrition, Medicare Advantage dynamics, and care enablement business momentum. The company expects mid-teens EBITDA growth despite Medicaid headwinds. A cybersecurity incident is under investigation, and a new 'premiums at risk' disclosure was introduced for ACO business transparency.

$ASTHHighAI 8/10

Astrana Health (ASTH) Q3 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). Membership grew to 1.5M, with Medicare Advantage increasing organically. The company completed acquisitions and partnerships, expanding its presence. Medical cost trends were slightly better than expected, with Texas operations performing ahead of plan. Free cash flow reached $105M, and net leverage was reduced to 2.2x.

$ASTHMed

Astrana Health Q3 Earnings Call Highlights

Astrana Health reported 1.5 million members under management, with Medicare Advantage growth offsetting Medicaid attrition. The company expects Medicaid membership to decline 10-15% in 2027, impacting adjusted EBITDA. Medical cost trends were slightly better than expected, with Medicare Advantage margins stable. Astrana plans 82% of capitation revenue from full-risk arrangements by 2026 and completed acquisitions and partnerships.